NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis $18.25 +0.10 (+0.55%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$18.08▼$18.6250-Day Range$6.53▼$18.1552-Week Range$6.20▼$41.78Volume1,958 shsAverage Volume58,019 shsMarket Capitalization$24.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pieris Pharmaceuticals alerts: Email Address Pieris Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish7.70% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment-0.18Based on 5 Articles This WeekInsider TradingAcquiring Shares$92,310 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.02 out of 5 starsMedical Sector805th out of 924 stocksPharmaceutical Preparations Industry377th out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals.Read more about Pieris Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.70% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently increased by 887.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePieris Pharmaceuticals has received a 71.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Pieris Pharmaceuticals is -0.81. Previous Next 1.6 News and Social Media Coverage News SentimentPieris Pharmaceuticals has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for PIRS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,310.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.89% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pieris Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pieris Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIhidden income trade in Apple?Is there a HUGE hidden income opportunity within Apple stock? Well, a brand new report suggests that is the case. And it’s all based on a “twist” on income trading hidden right inside one of the top stocks ever.Tap Here to Learn More About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More PIRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Stock News HeadlinesAugust 13, 2024 | insidertrades.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 SharesAugust 18, 2024 | americanbankingnews.comPieris Pharmaceuticals (NASDAQ:PIRS) Downgraded by StockNews.com to SellAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 16, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of ShareholdersAugust 16, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRSAugust 16, 2024 | bizjournals.comInside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firmAugust 16, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 15, 2024 | msn.comPIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024August 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 14, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 13, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRSAugust 13, 2024 | americanbankingnews.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of StockAugust 13, 2024 | americanbankingnews.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Acquires 3,000 SharesJuly 25, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of ShareholdersJuly 24, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.July 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersJuly 24, 2024 | investorplace.comWhy Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?July 24, 2024 | msn.comTraders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity FuturesSee More Headlines Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today8/22/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees140Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-39.71% Pretax Margin-39.71% Return on Equity-93.90% Return on Assets-58.33% Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92 Sales & Book Value Annual Sales$20.87 million Price / Sales1.15 Cash FlowN/A Price / Cash FlowN/A Book Value$21.66 per share Price / Book0.84Miscellaneous Outstanding Shares1,320,000Free Float1,203,000Market Cap$23.96 million OptionableOptionable Beta0.68 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Comp: $744.13kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Comp: $487.5kDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Comp: $463.91kMaria KelmanExecutive Director of Investor RelationsMr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project LeadershipMore ExecutivesKey CompetitorsFibroGenNASDAQ:FGENPowerUp AcquisitionNASDAQ:PWUPAlloVirNASDAQ:ALVRAclaris TherapeuticsNASDAQ:ACRSSagimet BiosciencesNASDAQ:SGMTView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPSold 8,735,663 shares on 8/15/2024Ownership: 3.295%Adar1 Capital Management, LlcBought 3,000 shares on 8/12/2024Total: $47,640.00 ($15.88/share)Adar1 Capital Management, LlcBought 3,000 shares on 8/9/2024Total: $44,670.00 ($14.89/share)Renaissance Technologies LLCSold 1,418,117 shares on 8/9/2024Ownership: 0.869%Acadian Asset Management LLCSold 951,531 shares on 8/6/2024Ownership: 0.820%View All Insider TransactionsView All Institutional Transactions PIRS Stock Analysis - Frequently Asked Questions How have PIRS shares performed this year? Pieris Pharmaceuticals' stock was trading at $14.56 at the beginning of the year. Since then, PIRS shares have increased by 25.3% and is now trading at $18.25. View the best growth stocks for 2024 here. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting analysts' consensus estimates of ($19.20). The biotechnology company earned $4.06 million during the quarter, compared to analyst estimates of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 93.90% and a negative net margin of 39.71%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals shares reverse split before market open on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Pieris Pharmaceuticals' major shareholders? Top institutional shareholders of Pieris Pharmaceuticals include Lynx1 Capital Management LP (3.30%), Renaissance Technologies LLC (0.87%) and Acadian Asset Management LLC (0.82%). Insiders that own company stock include Adar1 Capital Management, Llc, Christopher P Kiritsy, Tim Demuth and Shane Olwill. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN) and Dynavax Technologies (DVAX). This page (NASDAQ:PIRS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
